dbt Labs announced a definitive agreement to merge with Fivetran in an all-stock deal in October 2025, a combination that, if it closes, would unite two of the modern data stack's most widely used tools, dbt for data transformation and modeling, Fivetran for automated data ingestion and pipeline connectors, under a single company rather than the loosely coupled, separately-maintained integration that most data teams currently rely on. The two tools have long been complementary rather than competitive: a typical modern data pipeline uses Fivetran or a similar tool to pull data from source systems, SaaS APIs, application databases, third-party services, into a warehouse, and then uses dbt to transform that raw ingested data into clean, modeled tables ready for analytics and downstream consumption. Because they've historically been built and maintained by entirely separate companies, integration between the two has depended on both vendors independently prioritizing compatibility and a smooth handoff between ingestion and transformation stages, which works well enough today but leaves teams exposed to roadmap misalignment between two companies with different priorities and release cadences. A merged company controlling both ends of that pipeline could meaningfully tighten that integration, unified metadata and lineage tracking spanning ingestion through transformation, more consistent tooling and observability across the full pipeline, but also concentrates a larger share of a typical data team's toolchain under a single vendor's pricing and roadmap decisions. As of 2026, the merger remains pending regulatory approval, and data engineering teams currently relying on both tools should watch for how quickly and how tightly the two product lines get integrated once, and if, the deal closes, since that will determine how much practical benefit shows up versus how much is simply corporate consolidation.